
    
      The safety, tolerability, pharmacokinetics, and pharmacodynamics of GB004 will be explored in
      a Phase 1b randomized controlled trial in adults subjects with active ulcerative colitis
      (UC). Subjects will be evaluated based on incidence of AEs, laboratory parameters, GB004
      serum and colonic tissue concentrations, and changes in the signs and symptoms of UC.
    
  